Report cover image

In Vitro Diagnostics Business Outlook, Volume 3, Issue 6 - Focus on Glucose Testing Overview

Publisher Kalorama Information
Published Dec 01, 2024
Length 35 Pages
SKU # KLI19430510

Description

In Vitro Diagnostics Business Outlook, Volume 3, Issue 6 - Focus on Glucose Testing Overview


(price includes 6 issues published every two months)In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually.

In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:

Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
  • A comprehensive view of the IVD market with test categories covered and company briefs
  • M&A activities, selected partnerships & collaborations, partnership deals, and more
  • Industry & region watch to help tailor strategies
  • Analysis of news and events and reporting on news not easily available

Table of Contents

35 Pages
MARKET ANALYSIS: IVD GLUCOSE TESTING
OVERVIEW OF IVD GLUCOSE TESTING
MARKET OUTLOOK
Table: Global Diabetes Sales, by Test Category, 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
Figure: Global Diabetes Testing Market, by Segment with CAGR 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
REGIONAL MARKET
Figure: Global Diabetes Prevalence, 20-79y, 2021 Estimates (per 1,000s)
Figure: Global Distribution, Diabetes Test Market, 2024 (%) (Glucose, HbA1c)
COMPANY BRIEFS
Abbott Diagnostics
Dexcom
Roche
EXECUTIVE NEWS BRIEFING
BRIEFS
Agilent Reorganizes Business Units
Natera Co-Founder Named R&D Leader of the Year
QIAGEN Moves QIAstat-Dx to Drive Growth
OraSure Receives Funding
AmplifiDx Captures Additional Funding
52North Closes $6 Million in Funding
FINANCIAL HIGHLIGHTS: ABBOTT LABORATORIES, QIAGEN
ABBOTT CONTINUES STEADY PERFORMANCE IN 2024; 9M SALES INCREASE 3.7%
Figure: Abbott Sales by Business, 9M 2023 and 9M 2024 ($ million)
Table: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
Figure: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
Table: COVID-19 Test Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
Figure: Diabetes Care, Abbott Laboratories, 9M 2023 and 9M 2024 ($ million)
QIAGEN REPORTS STRONG PERFORMANCE IN Q3 2024; RAISES GUIDANCE
Figure: QIAGEN Revenue Mix by Business Segment, 9M 2024 ($ million) (Molecular Diagnostics, Life Sciences)
Figure: QIAGEN Sales by Product Group, 9M 2024 ($ million) (Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, Other)
Table: QIAGEN Sales, by Product Type, 9M 2023 and 9M 2024 ($ million) (CAGR %) (Consumables and Related Revenues, Instruments)
Figure: QIAGEN Diagnostic Solutions Sales, by Segment, 9M 2023 and 9M 2024 ($ million) (QuantiFERON, QIAstat-Dx, NeuMoDx, Other)
Figure: QIAGEN Sales, by Geographic Region, 9M 2023 and 9M 2024 ($ million) (Americas, EMEA, Asia Pacific/Japan)
DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
PARTNERSHIPS AND COLLABORATIONS
MERGERS AND ACQUISITIONS
Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals, Dec. 2023-Nov. 2024
INDUSTRY WATCH
INDUSTRY WATCH COVID-19/FLU UPDATE
REGION WATCH
VIETNAM
Figure: Vietnam GDP, Composition by Sector, 2023 (%) (Agriculture, Forestry, Fishery; Industry, Construction; Services)
Figure: Vietnam GDP Value and Growth by Year, 2015-2023 ($ billion)
BROAD-BASED COMPANY ANNOUNCEMENTS
ANNOUNCEMENTS
Roche Receives FDA Expanded Approval
Foundation Medicine Received FDA Companion Diagnostic Approval
Deepull Receives FDA Breakthrough Device Designation
bioMérieux Snags Clearance for Tropical Fever Panel
Roche Receives CE Mark for New Cobas Systems 2.0
Agilent Received Certification for Companion Diagnostic

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us